The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $42.53, marking a -0.84% move from the previous day.

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look ...

COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...

Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...

VKTX’s Non-Obesity Pipeline Shows Potential Apart from VK2735, Viking is also developing drugs targeting non-alcoholic steatohepatitis (NASH) and X-linked adrenoleukodystrophy (X-ALD ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $42.68 which represents a slight increase of $0.33 or 0.78% from the prior close of $42.35. The stock opened at $41.94 and ...